Two Studies Support Short Dual Antiplatelet Therapy With Abbott’s Xience DES
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
You may also be interested in...
The agency approved Medtronic's zotarolimus-eluting coronary stent for patients with a high bleeding risk who are treated with one month of dual-antiplatelet therapy.
The bioabsorbable polymer-coated, sirolimus-eluting stent is the first drug-eluting stent approved for this population.
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.